Novartis - Reimagining the standard of care in PsA and axSpA


Industry room 3
English
Satellite Symposia
02 June 2021 18:15 - 19:45

Learning Objectives:

To educate attendees on the: 

  • Importance of limiting progression from psoriasis and intercepting early PsA disease from both a dermatologist’s and rheumatologist’s perspective 
  • Need for early diagnosis and early treatment of axial SpA, in order to improve patient outcomes 
  • Recent update to GRAPPA treatment recommendation pillars in PsA, and discuss IL-17A inhibition data in relation to these pillars, for example IL-17A inhibition data in terms of efficacy across the key manifestations of PsA and safety 

Presentations

Title Time Calendar .ics
Welcome
02 June 2021 18:15 - 18:20 .ics
Reimagining psoriatic disease: A dermatologist’s perspective
02 June 2021 18:20 - 18:35 .ics
Improving outcomes in early PsA: A rheumatologist’s perspective
02 June 2021 18:35 - 18:50 .ics
Discussion and Q&A
02 June 2021 18:50 - 19:00 .ics
Putting the patient first: Early intervention to improve outcomes in axSpA
02 June 2021 19:00 - 19:15 .ics
PsA treatment recommendations: Focus on IL-17 inhibition
02 June 2021 19:15 - 19:35 .ics
Q&A and closing remarks
02 June 2021 19:35 - 19:45 .ics